CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
To access this article, please choose from the options below
Supported in part by Leukaemia Research, Cancer Research UK, Association for International Cancer Research, and the Medical Research Council.
PII: S0037-1963(10)00002-8
doi:10.1053/j.seminhematol.2010.01.001
© 2010 Elsevier Inc. All rights reserved.
